Need Help? Contact Us.

Enquire now

LISA-TRACKER Duo Bevacizumab

Product Description

LISA-TRACKER Duo Bevacizumab is an enzyme linked immunoassay (ELISA) for the quantitative determination of Bevacizumab (anti-VEGF) and anti-Bevacizumab antibodies in human serum samples.

  • Comprehensive menu in inflammatory diseases and oncology
  • Validated on principle drug and biosimilars
  • Ready to use reagents
  • Standardised protocols from sample collection to result interpretation
  • Automation ready – protocols available on several open platform ELISA systems
    1. Cohen M.H. et al. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent non squamous non-small cell lung cancer, The oncologist, vol. 12, no 6, 2007, p. 713-718.
    2. Ferrara N. Discovery and development of Bevacizumab, an anti-VEGF antibody for treating cancer. Nature reviews Drug Discovery, 2004, Vol. 3.
    3. Ferrara N. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochemical and Biophysical Research Communications, 2005, 328-335.
    4. Gilbert R et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma, N Engl J Med, 2014; 370:699-708.
    5. Nugue G. Monitoring Monoclonal antibody delivery in oncology: the example of Bevacizumab. PLoS One. 2013, 8(8): e72021.
    6. Ternant D. An enzyme-Linked Immunosorbent Assay to study Bevacizumab Pharmacokinetics. The Drug Monit 2010; 32:647-652.

Add to Enquiry Basket

LISA-TRACKER Duo Bevacizumab


Related Products

Assays Certification Platform Clinical Area Portfolio RUO/IVD
LISA-TRACKER Bevacizumab CE Marked Therapeutic Drug Monitoring TDM IVD
LISA-TRACKER anti-Bevacizumab CE Marked Therapeutic Drug Monitoring TDM IVD
LISA-TRACKER Duo Rituximab CE Marked Therapeutic Drug Monitoring TDM IVD
LISA-TRACKER Duo Trastuzumab CE Marked Therapeutic Drug Monitoring TDM IVD
This site is registered on as a development site.